Evidence map›Paper›PMID 32495520›Full record

ArticleThoracic cancer2020

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

Norimitsu Kasahara, Hisao Imai, Ichiro Naruse, Yusuke Tsukagoshi, Mie Kotake, Noriaki Sunaga, Kyoichi Kaira, Toshitaka Maeno, Takayuki Asao, Takeshi Hisada

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Norimitsu KasaharaInnovative Medical Research Center, Gunma University Hospital, Maebashi, Japan.ORCID 0000-0001-6971-7411
Hisao ImaiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.ORCID 0000-0003-3097-4255
Ichiro NaruseDepartment of Respiratory Medicine, Hidaka Hospital, Takasaki, Japan.
Yusuke TsukagoshiDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Mie KotakeDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.
Noriaki SunagaDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.ORCID 0000-0002-5966-4579
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.ORCID 0000-0001-5548-7686
Toshitaka MaenoDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Takayuki AsaoInnovative Medical Research Center, Gunma University Hospital, Maebashi, Japan.
Takeshi HisadaGraduate School of Health Sciences, Gunma University, Maebashi, Japan.

Funding

Japan Society for the Promotion of Science 19K16855JSPS
6 · The paper itself

Abstract

backgroundLung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS) is an inflammation-related score based on C-reactive protein (CRP) and albumin concentrations, and has prognostic value in various cancer settings. This study aimed to evaluate whether GPS could predict response of NSCLC to EGFR-TKIs.

methodsThis retrospective multicenter study evaluated patients with NSCLC harboring EGFR mutations who received EGFR-TKI monotherapy from October 2006 to December 2016. GPS values were determined using CRP and albumin concentrations from before initiation of EGFR-TKIs. The Kaplan-Meier method and Cox proportional hazard models were used to evaluate progression-free survival (PFS) and overall survival (OS).

resultsIn 214 patients, 141, 43, and two patients had GPS values of 0, 1, and 2, respectively. The GPS independently predicted the efficacy of EGFR-TKIs; good GPS (0-1) conferred significantly better PFS (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.38-0.96, P = 0.03) and OS (HR: 0.56, 95% CI: 0.33-0.96, P = 0.03). Multivariate analysis confirmed that a good GPS (0-1) independently predicted good PFS and OS among patients who had PS of 0-1. Good GPS (0-1) independently predicted good OS among patients receiving treatment in first-line settings.

conclusionsThe GPS independently predicted the efficacy of EGFR-TKIs for EGFR-mutated NSCLC; however, further studies are needed to validate our findings. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Glasgow prognostic score (GPS) independently predicted the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutated NSCLC. WHAT THIS STUDY ADDS: The findings presented in this paper will help to identify patients who will be expected to experience limited or no response to EGFR-TKI treatment by using GPS.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesBiomarkerEGFR-TKIGlasgow prognostic scorenon-small cell lung cancer

Identifiers

PMID32495520
PMCPMC7396379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.